Trial Profile
A Randomized, Double Blinded, Phase IIb/III, Decentralized Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Participants With Mild to Moderate Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 18 Sep 2022
Price :
$35
*
At a glance
- Drugs B 244 (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions; Therapeutic Use
- Sponsors AOBiome
- 19 Oct 2017 Results presented in an AOBiome Media Release.
- 19 Oct 2017 According to an AOBiome media release, primary endpoint has been met. (number of participants demonstrating efficacy measured by Investigator Global Assessment)
- 20 Jul 2017 Status changed from active, no longer recruiting to completed.